Phase 3 Psoriasis Trial, Recruiting NCT07029516 Sponsor: Wooshin Labottach Co., Ltd. Condition: Psoriasis
Back to Psoriasis

Phase 3 Psoriasis Trial, Recruiting

NCT07029516
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older
  • People with fragile or brittle nails
  • People with a type of nail fungal infection called distal subungual onychomycosis (a fungal infection starting at the tip of the nail)
  • People with nail psoriasis that affects no more than 75% of the nail bed, confirmed by photos and assessed by the study doctor

Who may not be able to join:

  • People whose nail fungal infection starts at the base of the nail (proximal subungual onychomycosis), has spread toward the base of the nail, or affects more than 75% of the nail
  • People with other medical conditions known to cause unusual nail appearance, a weakened immune system, or serious problems with blood circulation in the hands or feet
  • People who have used a topical (applied to the skin or nail) antifungal or anti-psoriasis nail treatment in the past month, or an antifungal medication taken by mouth or injection in the past three months
  • People who have taken part in another clinical nail study in the past three months
  • People with a known allergy to any of the treatments used in the study
  • People with unrelated nail disorders, including other types of nail fungal infection, nail psoriasis, or nail problems caused by a genetic condition
  • People with other nail disorders, active or severe psoriasis elsewhere on the body, or other autoimmune or inflammatory diseases

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +393356641965

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Wooshin Labottach Co., Ltd.
Registry
ClinicalTrials.gov
Start date
1 February 2026
Est. completion
1 November 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Evaluation, based on adverse events numeber of the Multi-Function Hydrogel Nail Patch safety in adult humans affected by Fragility Nails, Onychomycosis and Nail Psoriasis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov